Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced ...

VS Hospitals is also running an exclusive Familial Cancer Screening Clinic that specialises in risk assessment. The clinic ...

Mainz Biomed will present its current flagship product, ColoAlert®, a molecular stool-based screening test for the early detection of colorectal cancer, as well as further upcoming diagnostic ...

Groundbreaking new mouse study turns what we know about cancer on its head - Approximately 226,650 new cases and 124,730 ...

The ICGEC-2 conference on cancer genetics and epigenetics, featuring AI-based approaches, launched at JSS Medical College, Mysuru.

Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, to launch and ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...

Mainz Biomed will use the opportunity to further strengthen relationships with key opinion leaders in gastroenterology, exchange insights on the future of cancer prevention, and present its current ...

Breastfeeding and childbirth have long been known to reduce the risk of breast cancer. Now medical researchers are gaining ...

Often celebrated as a pioneer of genetics alongside Francis Crick, racist and sexist remarks tarnished his reputation in ...

SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk®Hereditary Cancer Test —the gold ...